1 Article type: Original article

2 Title: Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-
3 19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an
4 mRNA vaccine to unvaccinated patients

5 Robert Whittaker (MSc)^{a*}, Anja Bråthen Kristofferson (PhD)^b, Beatriz Valcarcel Salamanca (PhD)^b,
6 Elina Seppälä (MD)^a, Karan Golestani (MD)^c, Reidar Kvåle (PhD)^{d, e}, Sara Viksmoen Watle (MD)^a, Eirik
7 Alnes Buanes (PhD)^{d, f}

8 Family names are underlined.

9 a) Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo,
10 Norway.

11 b) Department of Method Development and Analytics, Norwegian Institute of Public Health,
12 Oslo, Norway.

13 c) Department of Infection Control and Preparedness, Norwegian Institute of Public Health,
14 Oslo, Norway.

15 d) Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen,
16 Norway.

17 e) Department of Clinical Medicine, University of Bergen, Bergen, Norway.

18 f) Norwegian Intensive Care and Pandemic Registry, Haukeland University Hospital, Bergen,
19 Norway.

20 * Corresponding author: Robert Whittaker, Norwegian Institute of Public Health, Lovisenberggata 8,
21 0456, Oslo, Norway; Phone: +47 21 07 63 93; Email: Robert.Whittaker@fhi.no

22 Abstract

23 Objectives

24 With most of the Norwegian population vaccinated against COVID-19, an increasing number and
25 proportion of COVID-19 related hospitalisations are occurring among vaccinated patients. We
26 estimated the length of stay (LoS) in hospital and an intensive care unit (ICU), and risk of admission to
27 ICU and in-hospital death among COVID-19 patients ≥ 18 years who had been fully vaccinated with an
28 mRNA vaccine, compared to unvaccinated patients.

29 Methods

30 Using national registry data, we conducted a cohort study on SARS-CoV-2 positive patients
31 hospitalised in Norway between 1 February and 30 November 2021, with COVID-19 as the main
32 cause of hospitalisation. We ran Cox proportional hazards models to analyse differences in our
33 outcomes. Explanatory variables included vaccination status, age, sex, county of residence, regional
34 health authority, date of admission, country of birth, virus variant and underlying risk factors.

35 Results

36 We included 3,203 patients, of whom 716 (22%) were fully vaccinated (at least two doses or one
37 dose and previous SARS-CoV-2 infection). Fully vaccinated patients had a shorter overall LoS in
38 hospital (aHR for discharge: 1.61, 95%CI: 1.24–2.08), shorter LoS without ICU (aHR: 1.27, 95%CI:
39 1.07–1.52), and lower risk of ICU admission (aHR: 0.50, 95%CI: 0.37–0.69) compared to unvaccinated
40 patients. We observed no difference in the LoS in ICU, nor risk of in-hospital death between fully
41 vaccinated and unvaccinated patients.

42 **Conclusions**

43 Fully vaccinated patients hospitalised with COVID-19 in Norway have a shorter LoS and lower risk of
44 ICU admission than unvaccinated patients. These findings can support patient management and
45 ongoing capacity planning in hospitals.

46

47 Keywords: Norway; SARS-CoV-2; hospitalisation; length of stay; intensive care; mRNA vaccine;
48 breakthrough infection

49 Introduction

50 COVID-19 vaccination programmes have drastically reduced the burden of COVID-19 related
 51 hospitalisations and deaths (1-5). However, the risk of breakthrough cases of severe COVID-19 after
 52 vaccination remains, particularly among groups at higher risk of severe disease (6, 7).

53 Norway (population 5.4 million) started COVID-19 vaccination in December 2020, initially focusing on
 54 individuals ≥ 65 years, health care workers and individuals at increased risk of severe COVID-19 (8).

55 The mRNA vaccines Comirnaty® (BioNTech-Pfizer, Mainz, Germany/New York, United States) and
 56 Spikevax® (mRNA-1273, Moderna, Cambridge, United States) are the two predominant vaccines
 57 administered (9). National second dose coverage among ≥ 18 -year-olds reached 87% by 30 November
 58 2021. Persons with specific immunosuppressive conditions were offered a third dose as part of the
 59 primary series from September (10). Booster doses have been offered to persons ≥ 65 years and care
 60 home residents since October, and health care workers since November 2021 (11).

61 With high national vaccination coverage, an increasing number and proportion of COVID-19 related
 62 hospitalisations are occurring among vaccinated patients, characterised by advanced age and
 63 underlying comorbidities that increase the risk of severe COVID-19 (8, 12). It is therefore essential to
 64 understand how vaccination may affect clinical endpoints among patients who are hospitalised for
 65 COVID-19 to support patient management and capacity planning in hospitals. Published data on this
 66 are currently limited (13, 14).

67 We linked individual-level data from national registries to estimate the length of stay (LoS) in hospital
 68 (with and without intensive care unit (ICU) stay) and ICU, and risk of ICU admission and in-hospital
 69 death among COVID-19 patients ≥ 18 years in Norway who had been fully vaccinated with an mRNA
 70 vaccine, compared to unvaccinated patients.

71 Methods

72 Patient cohort

73 We conducted a cohort study on patients ≥ 18 years hospitalised between 1 February and 30
 74 November 2021 after a positive SARS-CoV-2 test and who had a national identity number registered.
 75 We included patients hospitalised ≤ 2 days before and ≤ 28 days following a positive SARS-CoV-2 test,
 76 where COVID-19 was the reported main cause of hospitalisation. Cases hospitalised with other or
 77 unknown main cause were excluded. We did not restrict admissions by LoS. The Alpha variant was
 78 the predominant circulating variant at the start of the study period, before being superseded by
 79 Delta in early July (15).

80 Data sources

81 We obtained data from the Norwegian national emergency preparedness registry for COVID-19 (16).
 82 This registry contains individual-level data on all laboratory-confirmed COVID-19 cases, COVID-19
 83 related hospitalisations and ICU admissions, and COVID-19 vaccinations among Norwegian residents.
 84 Further details on the data sources and national COVID-19 vaccination coverage over time by age
 85 group and number of doses, are presented in supplementary materials A, part 1. We extracted data
 86 from the preparedness registry on 14 December 2021, ensuring a minimum of 13 days follow-up
 87 since last date of hospitalisation.

88 Definition of COVID-19 vaccination status

89 Vaccination status was defined on the date of positive test for SARS-CoV-2:

- 90 1. Unvaccinated: Not vaccinated with a COVID-19 vaccine.
- 91 2. Fully vaccinated: Positive test ≥ 7 days after second dose with at least the absolute minimum
 92 interval between doses depending on vaccine type (17), or ≥ 7 days after first dose if
 93 previously diagnosed with a SARS-CoV-2 infection ≥ 21 days before vaccination.

We excluded patients vaccinated with only one dose, those who had received a second dose <7 days before date of positive test, and patients vaccinated with a non-mRNA vaccine only. We also excluded unvaccinated patients with reported reinfections of SARS-CoV-2.

Outcome measures

Our outcomes were discharge from hospital (with and without ICU admission), admission to ICU, discharge from ICU and in-hospital death. We calculated LoS as the time between first admission and last discharge. For patients with more than one registered hospital stay, we included time between stays, if the time between two consecutive stays was <24 hours. For LoS in ICU, we included time between consecutive stays if <12 hours. Separate stays were registered if a patient was discharged and readmitted, or if a patient was transferred between wards or hospitals. Patients with unknown date of discharge from their last stay were considered to still be hospitalised. In-hospital death was registered at discharge.

Data analysis

Explanatory variables used to analyse differences in our outcomes were vaccination status, age, sex, county of residence, regional health authority, date of admission, country of birth, virus variant and underlying risk factors (Table 1).

Outcomes were first explored univariably in a Cox proportional hazards model and by calculating Kaplan Meier curves, with right censoring of patients still admitted to hospital. Crude log hazard ratios together with medians and interquartile ranges (IQR) for LoS were obtained. Explanatory variables with a p value <0.2 were further explored in multivariable models. Forward model selection was performed based on Akaike Information Criterion. Vaccination status was maintained in all models regardless of significance. Continuous variables (date of admission and age) were tested as linear, spline or categorically. The multivariable model was checked for the assumption of

proportional hazard by checking Schoenfeld residuals, and some explanatory variables were stratified to satisfy the assumption. The adjusted log hazard ratios (aHR) obtained in the multivariable models were reported. We ran models on all patients ≥ 18 years, as well as for the following age subgroups: 18–64 years, 65–79 years and ≥ 80 years. Patients vaccinated with three doses were not analysed separately due to small numbers. LoS in ICU was not analysed for the age subgroups due to the small number of vaccinated patients admitted to ICU in each subgroup (≤ 50).

We also conducted sensitivity analyses by changing the definition of our study population, study period or our outcome definitions to further explore if our main results were robust (supplementary materials A, part 2). The statistical analysis was performed in R version 3.6.2.

Ethics

Ethical approval for this study was granted by Regional Committees for Medical Research Ethics - South East Norway, reference number 249509. The need for informed consent was waived.

Results

Description of cohort

During the study period, 3,541 reported cases of COVID-19 were hospitalised with COVID-19 as the main cause of hospitalisation ≤ 2 days before and ≤ 28 days after a positive SARS-CoV-2 test. Of these, 3,476 (98%) had a national identity number registered. We excluded 262 patients vaccinated with only one dose or a second dose < 7 days before date of positive test, four patients vaccinated with non-mRNA vaccines, one patient with unknown vaccine type and two unvaccinated patients who were reported as having been reinfected with SARS-CoV-2. We also dropped four patients who had a reported stay in ICU outside of their hospital stay, due to assumed incomplete reporting on hospital stays. Our study cohort included the remaining 3,203 patients.

The median time from positive test to hospitalisation was 5 days (IQR 1–8), and 3,157 (99%) patients were admitted within 14 days of positive test. In total, 583 (18%) patients were admitted to ICU. At the end of follow-up, 75 (2.3%) patients were still hospitalised. Of the 3,128 patients who had been discharged, 188 (6.0%) died in hospital. In total, 716 (22%) patients were fully vaccinated, of whom 666 (93%) had received two doses, 47 (6.6%) three doses and three (0.4%) one dose with a previous SARS-CoV-2 infection. Most patients (658, 92%) received a homologous Comirnaty regimen. A full breakdown of vaccine types and time between doses is presented in supplementary materials A, part 3. The median time from last dose to diagnosis was 174 days (IQR: 126–217). Age and the frequency of certain underlying risk factors such as cancer, chronic lung disease, heart disease, immunosuppression (due to illness or treatment) and kidney disease were higher among fully vaccinated patients. Detailed characteristics of the study cohort by vaccination status are presented in Table 1. Equivalent descriptive data per age subgroup are available in supplementary materials B.

Length of stay in hospital and intensive care, and risk of admission to intensive care and in-hospital death by vaccination status

Descriptive data and crude and adjusted hazard ratios for each outcome by age subgroup and vaccination status are presented in Tables 2 and 3, and Figure 1. Estimates from all univariable and multivariable models in the main analysis are presented in supplementary materials B and C.

Our multivariable models suggested that fully vaccinated patients ≥ 18 years had a shorter overall LoS in hospital (aHR for discharge: 1.61, 95%CI: 1.24–2.08) and shorter LoS without ICU admission (aHR: 1.28, 95%CI: 1.07–1.52) compared to unvaccinated patients. Considering exponential distribution of the survival data, an aHR for discharge of 1.61 translates into an average 38% shorter LoS ($1 - 1/1.61$) (18). Fully vaccinated patients also had a 50% lower risk of ICU admission (aHR: 0.50, 95%CI: 0.37–0.69) compared to unvaccinated patients. We did not observe a difference in the LoS in ICU (aHR:

1.03, 95%CI: 0.80–1.31), or risk of in-hospital death (aHR: 1.00, 95%CI: 0.54–1.85) between vaccinated and unvaccinated patients (Figure 1, Table 3).

By age subgroup, fully vaccinated patients 18–64 years had an average 48% shorter overall LoS (aHR for discharge: 1.91, 95%CI: 1.37–2.66), 32% shorter LoS without ICU admission (aHR: 1.46, 95%CI: 1.11–1.91) and 47% lower risk of ICU admission (aHR: 0.53, 95%CI: 0.32–0.88), compared to unvaccinated individuals. Fully vaccinated patients 65–79 years had an average 22% shorter overall LoS (aHR for discharge: 1.29, 95%CI: 1.10–1.52) and 36% lower risk of ICU admission (aHR: 0.64, 95%CI: 0.46–0.89) compared to unvaccinated patients. There was no difference in the adjusted risk of in-hospital death between vaccinated and unvaccinated patients in any age subgroup. We did not observe a difference between vaccinated and unvaccinated patients ≥80 years in adjusted estimates for any outcome.

Results were generally robust in our sensitivity analyses, including when we analysed a period after which all persons in different age subgroups had been offered two vaccine doses, and when we excluded patients who had received three doses (supplementary materials A, part 2).

Discussion

In this national register-based study, we have analysed individual-level data on 3,203 hospitalised COVID-19 patients, during a period when the majority were offered mRNA vaccines in a two-dose schedule. In line with other reports (7, 13, 14, 19), vaccinated patients were generally older and had a higher prevalence of underlying risk factors than unvaccinated patients. We find that fully vaccinated patients had a shorter LoS in hospital (both with and without ICU admission) and lower risk of ICU admission compared to unvaccinated patients. There was no difference in the LoS in ICU, or risk of in-hospital death.

Our results suggest that once hospitalised the risk of death among fully vaccinated and unvaccinated patients in Norway is similar. However, for survivors the disease trajectory is milder in fully

vaccinated patients, with reduced need for hospital care and organ support. For patients not admitted to ICU, the observed reduction in LoS may have been attenuated by vaccinated patients, who may have ended up in ICU if unvaccinated, now instead spending more time in regular wards. The greatest relative reductions in LoS and risk of ICU admission were observed among patients 18–64 years. For all outcomes, we observed no difference between vaccinated and unvaccinated patients ≥ 80 years. Vaccine effectiveness against hospitalisation has been reported to be lower among older age groups in Norway (20). This age group is also generally less frequently admitted to ICU, and it could be that treatment limitations confound vaccine effects in the elderly. However, the small number of unvaccinated patients ≥ 80 years should be considered. Our results also highlight that factors other than vaccination also continue to influence patient outcomes. A longer LoS and/or increased risk of ICU admission or death were associated with advanced age, male sex and certain risk factors such as immunosuppression, kidney disease, obesity and diabetes, as reported by others (21–24).

These findings build on previous evidence of high vaccine effectiveness against severe disease (1–5, 20) and have important implications for patient management and ongoing capacity planning in hospitals. A study including 142 patients fully vaccinated with an mRNA vaccine from 21 sites across the United States also reported a shorter LoS, lower risk of death or invasive mechanical ventilation and a lower level of clinical disease severity among vaccinated patients (13). In contrast, a study from Michigan, United States did not find lower risk of ICU admission, mechanical ventilation or death when comparing 129 fully vaccinated patients (vaccinated with Comirnaty, Spikevax or Janssen) to unvaccinated patients (14). Differences in the study cohorts, setting and design need to be considered. In this study we compare fully vaccinated and unvaccinated patients, however vaccination programmes are continuing to evolve and future analyses will be necessary to explore how parameters such as vaccine type, number of doses, time since vaccination and dose intervals affect patient outcomes between groups of vaccinated patients. While studies have suggested sustained high effectiveness of mRNA vaccines against hospitalisation at least six months following

212 vaccination (25, 26), the duration of protection following the original two-dose schedules for mRNA
213 vaccines and the effects of booster doses (27, 28) require ongoing research.

214 A strength of our study is that all data sources had national coverage. We also had a notably larger
215 cohort of fully vaccinated patients compared to previous studies (13, 14). Also, hospitals in Norway
216 functioned within capacity during the study period, and criteria for hospitalisation and isolation for
217 COVID-19 patients were consistent and not related to vaccination status. Although we did not have
218 access to treatment data, there were no major changes in treatment guidelines for COVID-19
219 patients in hospital or ICU in Norway during the study period. We also had minimal censoring of the
220 study cohort, with 2.3% of patients still admitted to hospital at the end of follow-up.

221 Our study also has limitations. While we have controlled for several important confounders, the
222 observational nature has the potential for residual confounding. Our fully vaccinated cohort is also
223 predominantly representative of patients who received a homologous Comirnaty regimen. Another
224 limitation is that some of our reported underlying risk factors do not distinguish potential differences
225 within groups, for example whether risk factors are well-regulated or treated. Also, 40% of patients
226 had unknown body mass index. Our model may therefore not fully adjust for certain underlying risk
227 factors. Further, our study cohort does not include care home residents who in Norway are generally
228 recommended to receive treatment for severe COVID-19 in their care home, not in hospital. Finally,
229 previous natural infection has been associated with a high level of protection against SARS-CoV-2
230 reinfection (29, 30). While we dropped two reported reinfections, we cannot rule out that there
231 were other previously undiagnosed SARS-CoV-2 infections in our unvaccinated cohort. If present, this
232 may cause us to underestimate the effect of vaccination.

233 Our study suggests that mRNA vaccinated patients hospitalised with COVID-19 in Norway have a
234 shorter LoS and lower risk of ICU admission than unvaccinated patients. These findings can support
235 patient management and ongoing capacity planning in hospitals and underline the importance of
236 vaccination programmes against COVID-19.

Transparency declaration

Authors' contributions

RW, ABK, BVS, ES, RK and EAB conceived the idea for the study. RW drafted the study protocol and coordinated the study. RK and EAB contributed directly to the acquisition of data. RW and ABK contributed to data cleaning, validation and preparation. RW and ABK led the data analysis. All co-authors contributed to the interpretation of the results. RW and ABK drafted the manuscript. All co-authors contributed to the revision of the manuscript and approved the final version for submission.

Conflict of interest

The authors declare that they have no competing interests.

Funding

The authors received no specific funding for this work.

Acknowledgements

First and foremost, we wish to thank all those who have helped establish, coordinate and report data to the national emergency preparedness registry at the Norwegian Institute of Public Health (NIPH) throughout the pandemic. We also highly acknowledge the efforts of staff at hospitals around Norway to ensure the reporting of timely and complete data to the Norwegian Intensive Care and Pandemic Registry, as well as colleagues at the register itself. We would like to specifically thank Trude Marie Lyngstad, Jostein Starrfelt, Håkon Bøås and Lamprini Veneti at the NIPH for their assistance in cleaning the data from different registries, and additionally Trude Marie Lyngstad for assistance in the production of Figure S1.

Access to data

The dataset analysed in the study contains individual-level linked data from various central health registries, national clinical registries and other national administrative registries in Norway. The researchers had access to the data through the national emergency preparedness registry for COVID-19 (Beredt C19), housed at the Norwegian Institute of Public Health (NIPH). In Beredt C19, only fully anonymised data (i.e. data that are neither directly nor potentially indirectly identifiable) are permitted to be shared publicly. Legal restrictions therefore prevent the researchers from publicly sharing the dataset used in the study that would enable others to replicate the study findings. However, external researchers are freely able to request access to linked data from the same registries from outside the structure of Beredt C19, as per normal procedure for conducting health research on registry data in Norway. Further information on Beredt C19, including contact information for the Beredt C19 project manager, and information on access to data from each individual data source, is available at <https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/>.

References

1. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med*. 2021;385(7):585-94.
2. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet*. 2021;397(10285):1646-57.
3. Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. *Clin Infect Dis*. 2021.
4. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. 2021;397(10287):1819-29.
5. Glatman-Freedman A, Bromberg M, Dichtiar R, HersHKovitz Y, Keinan-Boker L. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data. *EBioMedicine*. 2021;72:103574.
6. Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. *BMJ*. 2021;374:n2244.
7. Brosh-Nissimov T, Orenbuch-Harroch E, Chowders M, Elbaz M, Nesher L, Stein M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. *Clin Microbiol Infect*. 2021.

- 294 8. Norwegian Institute of Public Health. Who will get the coronavirus vaccine? 2021 [cited 2021
295 Dec 15]. Available from: [https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-
296 programme/who-will-get-coronavirus-vaccine-first/](https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/)
- 297 9. Norwegian Institute of Public Health. Coronavirus vaccine - information for the public. 2021
298 [cited 2021 Dec 15]. Available from: [https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-
299 programme/who-will-get-coronavirus-vaccine-first/](https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/)
- 300 10. Norwegian Institute of Public Health. Personer med nedsatt immunforsvar anbefales en
301 tredje vaksinedose. Oslo: Norwegian Institute of Public Health. 2021 [cited 2021 Dec 15]. Available
302 from: [https://www.fhi.no/nyheter/2021/personer-med-nedsatt-immunforsvar-anbefales-en-tredje-
303 vaksinedose/](https://www.fhi.no/nyheter/2021/personer-med-nedsatt-immunforsvar-anbefales-en-tredje-vaksinedose/)
- 304 11. Norwegian Institute of Public Health. Flere anbefales tre doser med koronavaksine. 2021
305 [cited 2021 Dec 15]. Available from: [https://www.fhi.no/nyheter/2021/flere-anbefales-tre-doser-
306 med-koronavaksine/](https://www.fhi.no/nyheter/2021/flere-anbefales-tre-doser-med-koronavaksine/)
- 307 12. Norwegian Institute of Public Health. Ukerapporter om coronavirus og covid-19. Oslo:
308 Norwegian Institute of Public Health. 2021 [cited 2021 Dec 15]. Available from:
309 <https://www.fhi.no/publ/2020/koronavirus-ukerapporter/>
- 310 13. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, Ghamande S, et al.
311 Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA.
312 2021. doi: 10.1001/jama.2021.19499.
- 313 14. Bahl A, Johnson S, Maine G, Garcia MH, Nimmagadda S, Qu L, et al. Vaccination reduces need
314 for emergency care in breakthrough COVID-19 infections: A multicenter cohort study. Lancet Reg
315 Health Am. 2021:100065.

- 316 15. Veneti L, Valcarcel Salamanca B, Seppälä E, Starrfelt J, Storm ML, Bragstad K, et al. No
317 difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and
318 Alpha variant in Norway. IJID. 2021. doi: 10.1016/j.ijid.2021.12.321
- 319 16. Norwegian Institute of Public Health. Emergency preparedness register for COVID-19 (Beredt
320 C19). 2021 [cited 2021 Dec 15]. Available from: [https://www.fhi.no/en/id/infectious-](https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/)
321 [diseases/coronavirus/emergency-preparedness-register-for-covid-19/](https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/)
- 322 17. Norwegian Institute of Public Health. Vanlige problemstillinger om koronasertifikat. 2021
323 [cited 2021 Dec 15]. Available from: [https://www.fhi.no/om/koronasertifikat/til-helsepersonell-](https://www.fhi.no/om/koronasertifikat/til-helsepersonell-vanlige-problemstillinger-om-koronasertifikat/)
324 [vanlige-problemstillinger-om-koronasertifikat/](https://www.fhi.no/om/koronasertifikat/til-helsepersonell-vanlige-problemstillinger-om-koronasertifikat/)
- 325 18. Barraclough H, Simms L, Govindan R. Biostatistics primer: what a clinician ought to know:
326 hazard ratios. J Thorac Oncol. 2011;6(6):978-82.
- 327 19. Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, et al.
328 COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57
329 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med. 2021.
- 330 20. Starrfelt J, Buanes EA, Juvet LK, Lyngstad TM, Rø GOI, Veneti L. Age and product dependent
331 vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a
332 national cohort study, January – September 2021. Medrxiv. 2021 [cited 2021 Dec 15]. Available from:
333 <https://www.medrxiv.org/content/10.1101/2021.11.12.21266222v1>
- 334 21. Suarez-Garcia I, Perales-Fraile I, Gonzalez-Garcia A, Munoz-Blanco A, Manzano L, Fabregate
335 M, et al. In-hospital death among immunosuppressed patients with COVID-19: Analysis from a
336 national cohort in Spain. PLoS One. 2021;16(8):e0255524.
- 337 22. Boelle PY, Delory T, Maynadier X, Janssen C, Piarroux R, Pichenot M, et al. Trajectories of
338 Hospitalization in COVID-19 Patients: An Observational Study in France. J Clin Med. 2020;9(10).

23. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ*. 2020;369:m1966.
24. Sjögren L, Stenberg E, Thuccani M, Martikainen J, Rylander C, Wallenius V, et al. Impact of obesity on intensive care outcomes in patients with COVID-19 in Sweden-A cohort study. *PLoS One*. 2021;16(10):e0257891.
25. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med*. 2021;27(9):1614-21.
26. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet*. 2021;398(10309):1407-16.
27. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *N Engl J Med*. 2021.
28. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. *Lancet*. 2021. doi: 10.1016/S0140-6736(21)02249-2.
29. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *Lancet*. 2021;397(10286):1725-35.
30. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet*. 2021;397(10280):1204-12.

361 Tables and figures

362 *Table 1. Characteristics of SARS-CoV-2 positive patients aged ≥18 years hospitalised with COVID-19 as*
363 *the main cause of hospitalisation, by vaccination status, Norway, 1 February – 30 November 2021*

Characteristics		Vaccination status	
		Unvaccinated (n=2487)	Fully vaccinated (n=716)
Sex	Male	1472 (59.2%)	414 (57.8%)
	Female	1015 (40.8%)	302 (42.2%)
		p = 0.531	
Age group	18-29 years	157 (6.3%)	6 (0.8%)
	30-44 years	640 (25.7%)	32 (4.5%)
	45-54 years	645 (25.9%)	49 (6.8%)
	55-64 years	510 (20.5%)	93 (13.0%)
	65-79 years	453 (18.2%)	260 (36.3%)
	≥80 years	82 (3.3%)	276 (38.5%)
		p < 0.001	
Median age	In years (IQR)	51 (41–62)	76 (64–83)
		p < 0.001	
Born in Norway	Yes, with at least one parent born in Norway	1037 (41.7%)	546 (76.3%)
	Yes, two parents born outside of Norway	62 (2.5%)	4 (0.6%)
	No	1311 (52.7%)	113 (15.8%)
	Unknown	77 (3.1%)	53 (7.4%)

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

			p < 0.001
Underlying risk factors	Asthma	272 (10.9%)	74 (10.3%)
	Cancer ^a	63 (2.5%)	93 (13.0%)
	Chronic lung disease, excluding asthma	134 (5.4%)	143 (20.0%)
	Chronic neurological or neuromuscular disease	88 (3.5%)	60 (8.4%)
	Diabetes (type 1 and 2)	352 (14.2%)	166 (23.2%)
	Heart disease, including hypertension	659 (26.5%)	433 (60.5%)
	Immunosuppression, including HIV and immunosuppressive treatment ^b	63 (2.5%)	96 (13.4%)
	Kidney disease, including kidney failure	73 (2.9%)	126 (17.6%)
	Liver disease, including liver failure	24 (1.0%)	13 (1.8%)
	BMI ≥30 ^c	585 (23.5%)	104 (14.5%)
	Pregnant	66 (2.7%)	1 (0.1%)
	Current smoker	104 (4.2%)	25 (3.5%)
			p < 0.001
Virus variant	Alpha	1038 (41.7%)	12 (1.7%)
	Beta	22 (0.9%)	1 (0.1%)
	Delta	375 (15.1%)	341 (47.6%)
	Non-VOC	70 (2.8%)	3 (0.4%)
	Uncategorised ^d	58 (2.3%)	2 (0.3%)
	Unknown	924 (37.2%)	357 (49.9%)
			p < 0.001

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Month of admission	February	197 (7.9%)	0 (0.0%)
	March	733 (29.5%)	6 (0.8%)
	April	560 (22.5%)	9 (1.3%)
	May	201 (8.1%)	3 (0.4%)
	June	97 (3.9%)	4 (0.6%)
	July	48 (1.9%)	11 (1.5%)
	August	113 (4.5%)	44 (6.1%)
	September	161 (6.5%)	105 (14.6%)
	October	121 (4.9%)	167 (23.3%)
	November	256 (10.3%)	367 (51.3%)
			p < 0.001
Regional health authority	South-East	146 (5.9%)	86 (12.0%)
	West	142 (5.7%)	90 (12.6%)
	Mid	1919 (77.2%)	457 (63.8%)
	North	280 (11.3%)	83 (11.6%)
			p < 0.001
Admission to ICU	No	2007 (80.7%)	613 (85.6%)
	Yes	480 (19.3%)	103 (14.4%)
			p = 0.003
Death ^e	Died in ICU	67 (2.7%)	30 (4.4%)
	Died in hospital, not in ICU	35 (1.4%)	56 (8.2%)
	Alive at discharge	2346 (95.8%)	594 (87.4%)
			p < 0.001

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Number of patients	In ICU	18 (0.7%)	15 (2.1%)
still in hospital at end			
of follow-up (13	In hospital, not in ICU	21 (0.8%)	21 (2.9%)
December 2021)	Discharged from hospital	2448 (98.4%)	680 (95.0%)
			p < 0.001

364 IQR: interquartile range; VOC: Variant of concern; ICU: Intensive care unit; BMI: Body mass index. P values compared to unvaccinated
365 calculated using chi-squared tests or Wilcoxon rank sum tests as appropriate. P values for underlying risk factors based on proportion
366 having any one of the listed risk factors. Equivalent descriptive data per age subgroup are available in supplementary materials B.
367 ^a Refers to cancer patients undergoing treatment or with regular controls (>1 per year).
368 ^b Includes ongoing use of steroids in doses equivalent to at least 5mg Prednisolone daily.
369 ^c In our dataset, 1,270 patients (40%) had unknown information on height and weight, and thus unknown data on BMI. Of these 1,270, 962
370 were unvaccinated (39% of all unvaccinated) and 308 fully vaccinated (43%). In our models, BMI was therefore included as a three-level
371 categorical variable, yes, no and unknown.
372 ^d Cases for which VOC and non-VOC could not clearly be distinguished based on the available information. This does not potentially include
373 cases of the Omicron VOC, which was not detected in any patients in our study cohort.
374 ^e Excludes patients still in hospital at end of follow-up.

Figure 1. Adjusted hazard ratios for discharge from hospital with and without stay in intensive care, intensive care admission, discharge from intensive care, and in-hospital death from a Cox proportional hazards model, SARS-CoV-2 positive patients aged ≥ 18 years hospitalised with COVID-19 as the main cause of hospitalisation, by age, Norway, 1 February – 30 November 2021

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

380 ICU: Intensive care unit. The reference group with a hazard ratio = 1 is patients who are male, aged 56 years (median age in
381 dataset) without underlying risk factors and unvaccinated. Hazard ratios were calculated using a Cox proportional hazards model. The
382 variables shown in each panel are those significantly associated with each outcome in multivariable models, which were not stratified on
383 (see supplementary materials C). Akaike Information Criterion was used for determining whether age was included linearly or with a spline.

384

Table 2. Number of patients, median number of days from admission to discharge from hospital or ICU, admissions to ICU and deaths in hospital, SARS-CoV-2 positive patients aged ≥ 18 years hospitalised with COVID-19 as the main cause of hospitalisation, by vaccination status and age group, Norway, 1 February – 30 November 2021

Age group	Number of patients	Median number of days from admission to discharge from hospital (IQR) ^a	Median number of days from admission to discharge, patients not admitted to ICU (IQR) ^a	Number of patients admitted to ICU (%)	Median number of days from admission to discharge from ICU (IQR) ^{a, b}	Number of deaths in hospital (%) ^c
Unvaccinated						
18–64 years	1952	4.8 (2.5–8.7)	3.9 (2.0–6.5)	343 (18%)	-	38 (2.0%)
65–79 years	453	7.1 (3.8–14.2)	5.0 (3.0–8.7)	131 (29%)	-	47 (11%)
≥ 80 years	82	5.6 (2.9–8.0)	5.4 (2.9–7.1)	6 (7.3%)	-	17 (21%)
≥ 18 years	2487	5.0 (2.7–9.6)	4.0 (2.1–6.8)	480 (19%)	9.9 (5.3–18.0)	102 (4.2%)
Fully vaccinated						
18–64 years	180	4.1 (2.0–10.6)	3.4 (1.6–6.5)	35 (19%)	-	9 (5.4%)
65–79 years	260	7.0 (3.3–12.4)	5.9 (2.8–9.2)	50 (19%)	-	33 (14%)
≥ 80 years	276	4.7 (2.2–9.1)	4.1 (2.1–8.1)	18 (6.5%)	-	61 (16%)
≥ 18 years	716	5.2 (2.6–10.5)	4.2 (2.1–8.1)	103 (14%)	9.9 (4.1–17.7)	86 (13%)

388

389 ICU: Intensive care unit; IQR: Interquartile range.

390 ^a Estimates from univariable Cox regression, see supplementary materials B.

391 ^b Median number of days from admission to discharge from ICU not presented for age subgroups due to the small number of fully vaccinated patients admitted to ICU in each age subgroup (≤ 50).

392 ^c Proportions calculated excluding those still admitted at the end of the study period. 18–64 years: 25 unvaccinated, 12 fully vaccinated; 65–79 years: 13 unvaccinated, 17 fully vaccinated; ≥ 80 years: 1 unvaccinated, 7
393 fully vaccinated.

Table 3. Crude and adjusted hazard ratios for discharge from hospital with and without stay in intensive care, intensive care admission, discharge from intensive care, and in-hospital death from a Cox proportional hazards model, SARS-CoV-2 positive patients aged ≥ 18 years hospitalised with COVID-19 as the main cause of hospitalisation, by age group, Norway, 1 February – 30 November 2021

Age group	Discharge from hospital		Discharge from hospital, patients not admitted to ICU		ICU admission		Discharge from ICU		Death in hospital	
	Crude hazard ratio compared to unvaccinated (95%CI)	Adjusted ^a hazard ratio compared to unvaccinated (95%CI)	Crude hazard ratio compared to unvaccinated (95%CI)	Adjusted ^a hazard ratio compared to unvaccinated (95%CI)	Crude hazard ratio compared to unvaccinated (95%CI)	Adjusted ^a hazard ratio compared to unvaccinated (95%CI)	Crude hazard ratio compared to unvaccinated (95%CI) ^b	Adjusted ^{a,b} hazard ratio compared to unvaccinated (95%CI)	Crude hazard ratio compared to unvaccinated (95%CI)	Adjusted ^a hazard ratio compared to unvaccinated (95%CI)
18–64 years	0.913 (0.779–1.069)	1.909 (1.372–2.658)	0.962 (0.811–1.142)	1.455 (1.106–1.914)	1.137 (0.803–1.610)	0.530 (0.319–0.882)	-	-	2.177 (1.050–4.516)	1.351 (0.636–2.871)
65–79 years	1.173 (1.001–1.375)	1.287 (1.092–1.517)	0.866 (0.725–1.034)	1.218 (0.939–1.580)	0.627 (0.453–0.869)	0.639 (0.461–0.886)	-	-	1.687 (1.074–2.651)	1.427 (0.892–2.284)
≥ 80 years	1.117 (0.869–1.434)	1.080 (0.839–1.389)	1.043 (0.806–1.349)	0.996 (0.769–1.290)	0.953 (0.378–2.403)	0.910 (0.361–2.295)	-	-	0.829 (0.473–1.453)	0.765 (0.436–1.340)
≥ 18 years	0.981 (0.901–1.068)	1.607 (1.243–2.077)	0.785 (0.716–0.861)	1.272 (1.068–1.516)	0.689 (0.556–0.852)	0.503 (0.368–0.689)	1.027 (0.817–1.292)	1.025 (0.803–1.308)	3.229 (2.417–4.315)	0.995 (0.536–1.847)

ICU: Intensive care unit; 95%CI: 95% confidence interval. Bold text = statistically significant results.

^a Adjusted for age, sex, county of residence, regional health authority, date of admission, country of birth, virus variant and underlying risk factors (Table 1). The variables included in the final multivariable models were obtained by forward model selection based on Akaike Information Criterion (see supplementary materials C).

^b Not analysed for age subgroups due to the small number of fully vaccinated patients admitted to ICU in each age subgroup (≤ 50).